<DOC>
	<DOCNO>NCT00441701</DOCNO>
	<brief_summary>This two-part study conduct multiple center , navarixin ( SCH 527123 , MK-7123 ) participant moderate severe chronic obstructive pulmonary disease ( COPD ) . Part 1 study double-blind , placebo-controlled , randomize , rising-dose study consist four treatment group enrol three cohort . The duration treatment , cohort , 2-week run-in period , follow 12-week double-blind treatment period . Treatment initiation cohort stagger 4 week allow safety assessment prior use high dos navarixin . Part 2 study double-blind , placebo-controlled , randomize , parallel group study consist four treatment group enrol one cohort . The duration treatment consist 2-week run-in period , follow 12-week double-blind treatment period .</brief_summary>
	<brief_title>Study Evaluate Safety Dose-Range Navarixin ( SCH 527123 , MK-7123 ) Participants With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD ) ( MK-7123-012 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD base American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) criterion . &gt; 40 &lt; =75 year age , either sex , race . Current smoker least 10 packyears smoke history ( eg , 10 packyear history equal smoking 1 pack cigarette per day 10 year 2 pack per day 5 year ) . Participant counsel risk smoke available smoking cessation program prior enrollment . Participant elect continue smoke eligible enrollment . Once enrol , participant elect discontinue smoking , reduce cigarette consumption , he/she allow complete study . History daily sputum production least past 3 month . Postbronchodilator FEV1 must &gt; =800 mL , &gt; =40 % &lt; =70 % predict FEV1 . Postbronchodilator ratio FEV1 force vital capacity ( FVC ) must &lt; =70 % . Female participant childbearing potential must use medically acceptable , highly effective , adequate form birth control ( ie , failure rate le 1 % per year use consistently correctly ) prior Screening agree continue use study ( Screening Treatment Periods ) . Medically acceptable , highly effective form birth control hormonal implant , oral contraceptive , medically acceptable prescribed intrauterine device ( IUDs ) , monogamous relationship male partner vasectomy . Female participant encourage continue use highly effective method birth control 30 day follow end treatment . Female participant childbearing potential currently sexually active must agree use highly effective method contraception become sexually active participate study . Male participant must agree use adequate form contraception duration study agree sexual relation woman use highly effective birth control method accord note guidance nonclinical safety study conduct human clinical trial pharmaceutical ( CPMP/ICH/286/95 mod ) . A highly effective method birth control define result low failure rate ( ie , le 1 % per year ) use consistently correctly , hormonal implant , injectables , combine oral contraceptive , hormonal IUDs . Female participant childbearing potential must medical record surgically sterile ( eg , hysterectomy , tubal ligation ) , least 1 year postmenopausal . Absence menses least 1 year indicate female postmenopausal . Capable comply dose regimen visit schedule . Willing give write informed consent participate study . Diagnosed asthma clinically relevant lung disease ( COPD ) , eg , sarcoidosis , tuberculosis , pulmonary fibrosis , bronchiectasis , lung cancer . History previous lung surgery ( eg , lobectomy , pneumonectomy , lung volume reduction ) . Lower respiratory tract infection within 4 week prior Screening Visit . Receiving chronic antibiotic therapy . Exacerbation COPD within 4 week prior Screening Visit . &gt; 20 % change Screening postbronchodilator FEV1 . Female participant breastfeeding , pregnant , intend become pregnant study . Clinically relevant medical condition ( eg , hematologic , cardiovascular , renal , hepatic , neurologic , metabolic ) . Taken inhale systemic steroid within 4 week Screening Visit ( Visit 1 ) . Received investigational drug within last 30 day . Produced inadequate amount sputum Screening Visit ( Visit 1 ) know difficulty produce sputum . PBN count &lt; 3000 cells/microliters Screening Visit ( Visit 1 ) . Part staff personnel directly involve study . Family member investigational study staff . Received study prohibit medication recently indicate washout period , prior ( Screening ) , must continue receive prohibit treatment .</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>